We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 63

NHS procurement, patient choice and competition regulations 2013

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • March 19 2013

The NHS Procurement, Patient Choice and Competition Regulations 2013, which were covered in our previous alert have been revised. The revised

Access to clinical trial data - the irreversible process

  • Bird & Bird
  • -
  • European Union, United Kingdom
  • -
  • February 25 2013

The issue of ensuring transparency of the activities of regulators is nothing new, with public bodies being required to observe Freedom of

Monitor to gain competition law powers from 1 April

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • February 11 2013

Monitor, the NHS regulator, is to have powers to apply competition law to healthcare service providers from 1 April 2013. The competition law

British man imprisoned in ‘Operation Singapore’ investigation

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 3 2011

The UK MHRA's 'Operation Singapore' investigation into the infiltration of counterfeit medicine into the UK's supply chain during five months in 2007 has concluded with a British man being sentenced to eight years imprisonment

UK Patents Court judgment in Mölnlycke Health Care AB v Brightwake Limited: weight to be attached to experiments (2011 EWHC 376 (pat))

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 3 2011

In this case His Honour Judge Birss QC (the newly appointed Patents County Court judge) sitting as a judge of the Patents Court (High Court) considered infringement and validity of Mölnlycke's European Patent 0,633,757 (relating to wound dressings coated on one side with silicone gel

Can an authorisation for a human medicinal product provide basis for an SPC where its active was previously authorised in a veterinary medicinal product?

  • Bird & Bird
  • -
  • European Union, United Kingdom
  • -
  • May 3 2011

As exemplified by Cases 19509 Synthon v Merz and C-42709 Generics (UK) v Synaptech, currently pending before the Court of Justice of the European Union (CJEU), the recent opinions of the Advocate General which are discussed elsewhere in this update, one perennial source of controversy under the Supplementary Protection Certificate (SPC) Regulations is what sort of authorisation constitutes a "first marketing authorisation in the Community."

Court of Appeal judgment in KCI Licensing Inc & others v Smith & Nephew plc & others: contributory infringement through supply of negative pressure wound therapy device

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • January 31 2011

KCI sued Smith & Nephew (S&N) under two patents, EP (UK) patents Nos. 0 777 504 ('504) and 0 853 950 ('950), relating to negative pressure wound therapy ("NPWT") devices

Cephalon, Inc & Others v Orchid Europe Limited & Generics (UK): preliminary injunction refused despite failure of generic entrants to “clear the way”

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • January 31 2011

In his judgment of 19 November 2010 Mr Justice Floyd (2010 EWHC 2945 (Pat)) considered an application by Cephalon for a preliminary injunction to restrain infringement of its two EP(UK) patents (relating to modafinil (a drug used for the treatment of narcolepsy) in the form of particles of a defined size) by Orchid and Generics (UK) (trading as Mylan

Abbott Laboratories Limited v Medinol Limited, Patents Court, Chancery Division, High Court of Justice, London, UK, 12 November 2010, 2010 EWHC 2865 (PAT)

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • January 31 2011

Mr Justice Arnold ruled on 12 November 2010 that Abbott's eight coronary stents did not infringe any of Medinol's three patents, EP(UK) 0 846 449, 1 181 901 and 1 181 902

NICE provisionally recommends Alzheimer’s drugs for early and moderate stage treatment

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • October 21 2010

On 7 October 2010, NICE issued draft guidance, subject to appeal, recommending that Aricept (donepezil, manufactured by Eisai), Reminyl (galantamine, manufactured by Shire) and Exelon (rivastigmine, manufactured by Novartis) be made available to patients with early to moderate stage Alzheimer's disease

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy